


# INTERNATIONAL SEARCH REPORT

In  lational Application No  
PCT/DK2004/000242

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07J3/00 C07J31/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97/24365 A (GLAXO GROUP LTD ;BIGGADIKE KEITH (GB); PROCOPIOU PANAYIOTIS ALEXAN) . 10 July 1997 (1997-07-10) page 11, line 25 - page 13, line 6	1-22
X	WO 02/08243 A (COOTE STEVEN JOHN ;ROBINSON JOHN MALCOLM (GB); GLAXO GROUP LTD (GB) 31 January 2002 (2002-01-31) page 6, lines 1-15	1-16
X	GB 2 088 877 A (GLAXO GROUP LTD) 16 June 1982 (1982-06-16) page 3, line 51 - page 5, line 29	1-22
X	US 4 578 221 A (BAIN BRIAN M ET AL) 25 March 1986 (1986-03-25) examples 1-13 claims 1,7	1-16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

3 August 2004

Date of mailing of the international search report

18/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. S1 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Samsam Bakhtiary, M

# INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/DK2004/000242

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/12265 A (COOTE STEVEN JOHN ; BIGGADIKE KEITH (GB); GLAXO GROUP LTD (GB); NICE R) 14 February 2002 (2002-02-14) page 21, line 1 - page 22, line 25	1-16
X	HAPGOOD, JANET P. ET AL: "Steroid-affinity purification of the rat liver glucocorticoid hormone receptor complex" JOURNAL OF STEROID BIOCHEMISTRY ( 1987 , 28(6), 769-77 CODEN: JSTBBK; ISSN: 0022-4731, 1987, XP001183044 page 770, right-hand column, paragraph 2	17,18
X	HOYTE, R. M. ET AL: "Synthesis and evaluation of potential radioligands for the progesterone receptor" JOURNAL OF MEDICINAL CHEMISTRY ( 1985 ), 28(11), 1695-9 CODEN: JMCMAR; ISSN: 0022-2623, 1985, XP001182782 page 1696, right-hand column; compound 15	17,18
X	MACINDOE, JOHN H. ET AL: "Comparative studies of 5.alpha.-reductase inhibitors within MCF-7 human breast cancer cells" JOURNAL OF STEROID BIOCHEMISTRY ( 1984 , 20(5), 1095-100 CODEN: JSTBBK; ISSN: 0022-4731, 1984, XP001182781 page 1096, left-hand column, last paragraph - page 1096, right-hand column, line 11	17,18
X	FORMSTECHE, P. ET AL: "Synthesis of steroidal 17.beta.-carboxamide derivatives" STEROIDS ( 1980 ), 35(3), 265-72 CODEN: STEDAM; ISSN: 0039-128X, 1980, XP001182780 page 266 formula III	17-19
X	KOLBE, ADELHEID ET AL: "Syntheses of dexamethasone conjugates of the phytohormones gibberellin A3 and 24-epicastasterone" COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS ( 2002 ), 67(1), 103-114 CODEN: CCCCAK; ISSN: 0010-0765, 2002, XP001194682 page 104; compound 3	17-19

-/--

# INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/DK2004/000242

G.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HEUBNER, ARNULF ET AL: "Application of liquid-liquid partition chromatography in the simultaneous purification of sex-hormone-binding globulin and corticosteroid-binding globulin" JOURNAL OF CHROMATOGRAPHY ( 1987 ), 397, 419-34 CODEN: JOCRAM; ISSN: 0021-9673, 1987, XP001194688 page 420, paragraph 4	17-19
X	PHILLIPPS G H ET AL: "SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS IN A SERIES OF ANTIINFLAMMATORY CORTICOSTEROID ANALOGUES, HALOMETHYL ANDROSTANE-17BETA-CARBOETHIOATES AND-17BETA-CARBOSELENOATES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 22, 1 October 1994 (1994-10-01), pages 3717-3729, XP002025925 ISSN: 0022-2623 cited in the application page 3718 scheme 3	1-16
X	MANZ, BERNHARD ET AL: "Synthesis of biotin-labeled dexamethasone derivatives. Novel hormone-affinity probes" EUROPEAN JOURNAL OF BIOCHEMISTRY ( 1983 ), 131(2), 333-8 CODEN: EJBICAI; ISSN: 0014-2956, 1983, XP009034828 page 334; figure 1	17-19
X	GOVINDAN, MANJAPRA V. ET AL: "Three-step purification of glucocorticoid receptors from rat liver" EUROPEAN JOURNAL OF BIOCHEMISTRY ( 1980 ), 108(1), 47-54 CODEN: EJBICAI; ISSN: 0014-2956, 1980, XP009034821 page 47, right-hand column, last paragraph	17-19

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/DK2004/000242

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9724365	A	10-07-1997	AT 194356 T	15-07-2000
			AU 721865 B2	13-07-2000
			AU 1140997 A	28-07-1997
			BG 102625 A	30-04-1999
			BR 9612309 A	13-07-1999
			CA 2241728 A1	10-07-1997
			CN 1209135 A , B	24-02-1999
			CZ 9802074 A3	11-11-1998
			DE 69609199 D1	10-08-2000
			DE 69609199 T2	01-03-2001
			DK 876392 T3	06-11-2000
			EA 1401 B1	26-02-2001
			EE 9800227 A	15-12-1998
			EP 0876392 A1	11-11-1998
			ES 2150150 T3	16-11-2000
			WO 9724365 A1	10-07-1997
			GR 3034564 T3	31-01-2001
			HK 1012193 A1	23-01-2001
			HU 9903707 A2	28-03-2000
			JP 2947944 B2	13-09-1999
			JP 11501675 T	09-02-1999
			NO 983004 A	26-08-1998
			NZ 324373 A	28-10-1999
			OA 10701 A	21-05-2002
			PL 327629 A1	21-12-1998
			PT 876392 T	29-12-2000
			SI 876392 T1	31-12-2000
			SK 89198 A3	10-03-1999
			TR 9801247 T2	23-11-1998
			TW 498072 B	11-08-2002
			US 6197761 B1	06-03-2001
WO 0208243	A	31-01-2002	AU 7090601 A	05-02-2002
			BR 0110430 A	08-07-2003
			CA 2406963 A1	31-01-2002
			CN 1437610 T	20-08-2003
			CZ 20023472 A3	16-04-2003
			EP 1301526 A1	16-04-2003
			WO 0208243 A1	31-01-2002
			HU 0301108 A2	28-08-2003
			JP 2004504403 T	12-02-2004
			NO 20025054 A	05-11-2002
			NZ 522083 A	25-06-2004
			US 2004043974 A1	04-03-2004
GB 2088877	A	16-06-1982	CY 1291 A	18-10-1985
			AT 395428 B	28-12-1992
			AT 17084 A	15-05-1992
			AT 401521 B	25-09-1996
			AT 34491 A	15-02-1996
			AT 395427 B	28-12-1992
			AT 67481 A	15-05-1992
			AT 395429 B	28-12-1992
			AT 203186 A	15-05-1992
			AU 544517 B2	06-06-1985
			AU 6729881 A	20-08-1981
			BE 887518 A1	13-08-1981
			BG 60700 B2	29-12-1995

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/DK2004/000242

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2088877	A	CA 1201114 A1	25-02-1986
		CA 1205464 A2	03-06-1986
		CH 644615 A5	15-08-1984
		CH 651307 A5	13-09-1985
		CZ 9104034 A3	16-03-1994
		DE 3105307 A1	10-12-1981
		DE 3153379 C2	19-11-1992
		DK 62381 A ,B,	16-08-1981
		ES 8207194 A1	01-12-1982
		ES 8305379 A1	01-07-1983
		ES 8402317 A1	16-04-1984
		ES 8502447 A1	01-04-1985
		ES 8600936 A1	16-02-1986
		FI 810444 A ,B,	16-08-1981
		FR 2477156 A1	04-09-1981
		FR 2485542 A1	31-12-1981
		GB 2137206 A ,B	03-10-1984
		HK 58385 A	16-08-1985
		IE 51394 B1	24-12-1986
		IE 51395 B1	24-12-1986
		IT 1170717 B	03-06-1987
		JP 1488353 C	23-03-1989
		JP 56138200 A	28-10-1981
		JP 63037120 B	22-07-1988
		KE 3526 A	07-06-1985
		KR 8500969 B1	02-07-1985
		MX 9202717 A1	30-06-1992
		MY 75785 A	31-12-1985
		NL 84649 C	
		NL 960029 I1	03-02-1997
		NL 8100707 A ,B,	16-09-1981
		NZ 196260 A	30-11-1983
		PH 24267 A	29-05-1990
		PT 72502 A ,B	01-03-1981
		SE 452468 B	30-11-1987
		SE 8101010 A	16-08-1981
		SG 36885 G	15-11-1985
US 4578221	A	25-03-1986	
		AT 395428 B	28-12-1992
		AT 17084 A	15-05-1992
		AT 401521 B	25-09-1996
		AT 34491 A	15-02-1996
		AT 395427 B	28-12-1992
		AT 67481 A	15-05-1992
		AT 395429 B	28-12-1992
		AT 203186 A	15-05-1992
		AU 544517 B2	06-06-1985
		AU 6729881 A	20-08-1981
		BG 60700 B2	29-12-1995
		CH 644615 A5	15-08-1984
		CH 651307 A5	13-09-1985
		CZ 9104034 A3	16-03-1994
		DE 3105307 A1	10-12-1981
		DE 3153379 C2	19-11-1992
		DK 62381 A ,B,	16-08-1981
		ES 8207194 A1	01-12-1982
		ES 8305379 A1	01-07-1983
		ES 8402317 A1	16-04-1984

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/DK2004/000242

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4578221	A	ES 8502447 A1	01-04-1985
		ES 8600936 A1	16-02-1986
		FI 810444 A ,B,	16-08-1981
		FR 2477156 A1	04-09-1981
		FR 2485542 A1	31-12-1981
		GB 2137206 A ,B	03-10-1984
		HK 58385 A	16-08-1985
		IE 51394 B1	24-12-1986
		IE 51395 B1	24-12-1986
		IT 1170717 B	03-06-1987
		KE 3526 A	07-06-1985
		KR 8500969 B1	02-07-1985
		MX 9202717 A1	30-06-1992
		MY 75785 A	31-12-1985
		NL 84649 C	
		NL 960029 I1	03-02-1997
		NL 8100707 A ,B,	16-09-1981
		NZ 196260 A	30-11-1983
		PT 72502 A ,B	01-03-1981
		SE 452468 B	30-11-1987
		SE 8101010 A	16-08-1981
		SG 36885 G	15-11-1985
		SK 403491 A3	07-02-1996
		US 2794508 A	04-06-1957
		US 4650610 A	17-03-1987
WO 0212265	A	14-02-2002	
		AU 7576001 A	18-02-2002
		AU 7649701 A	18-02-2002
		BG 107518 A	30-09-2003
		BR 0113039 A	15-07-2003
		BR 0113042 A	08-07-2003
		CA 2417825 A1	14-02-2002
		CA 2417826 A1	14-02-2002
		CN 1468252 T	14-01-2004
		CN 1468253 T	14-01-2004
		CZ 20030353 A3	14-05-2003
		EP 1305329 A1	02-05-2003
		EP 1305330 A1	02-05-2003
		WO 0212265 A1	14-02-2002
		WO 0212266 A1	14-02-2002
		HU 0303084 A2	29-12-2003
		HU 0303354 A2	28-01-2004
		JP 2004505989 T	26-02-2004
		JP 2004505990 T	26-02-2004
		MA 25899 A1	01-10-2003
		NO 20030549 A	04-02-2003
		NO 20030550 A	04-04-2003
		SK 1422003 A3	03-06-2003
		US 2002177581 A1	28-11-2002
		US 2003073676 A1	17-04-2003
		US 2002173496 A1	21-11-2002
		US 2003153542 A1	14-08-2003
		US 2002165211 A1	07-11-2002
		US 2003109511 A1	12-06-2003
		US 2004028615 A1	12-02-2004
		US 2003199485 A1	23-10-2003
		US 2003045512 A1	06-03-2003
		US 2003092690 A1	15-05-2003

# PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

## PCT

To:  
ALPHARMA APS  
Dalslandsgade 11  
DK-2300 Copenhagen S  
DENMARK

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT AND  
THE WRITTEN OPINION OF THE INTERNATIONAL  
SEARCHING AUTHORITY, OR THE DECLARATION

(PCT Rule 44.1)

Applicant's or agent's file reference <b>2003-100 PC</b>	Date of mailing (day/month/year) <b>18/08/2004</b>
International application No. <b>PCT/DK2004/000242</b>	International filing date (day/month/year) <b>02/04/2004</b>
Applicant <b>ALPHARMA APS</b>	

1. ☒ The applicant is hereby notified that the international search report and the written opinion of the International Searching Authority have been established and are transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO, 34 chemin des Colombettes  
1211 Geneva 20, Switzerland, Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect and the written opinion of the International Searching Authority are transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

- ☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices,  
☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

**4. Reminders**


Shortly after the expiration of 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

The applicant may submit comments on an informal basis on the written opinion of the International Searching Authority to the International Bureau. The International Bureau will send a copy of such comments to all designated Offices unless an international preliminary examination report has been or is to be established. These comments would also be made available to the public but not before the expiration of 30 months from the priority date.

Within 18 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise, the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 18 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the *PCT Applicant's Guide*, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the International Searching Authority  European Patent Office, P.B. 5918 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <b>Josef Ullrich</b>
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------

6. Dec. 2004 18:52

Nr. 0454 S. 7

2003-100 PC

**CLAIMS**

1. A method for preparing a steroidal carbothioic acid or a salt thereof, said method comprises:  
 A) reacting a steroidal carboxylic acid or a salt thereof with a coupling agent selected from the  
 5 group consisting of carbodiimide derivatives represented by the following formula:



wherein  $R_a$  and  $R_b$  are the same or different, and each represent an aliphatic, heteroaliphatic, carbocyclic or a heterocyclic group [all said groups are optionally substituted];  
 alone or in conjunction with a coupling enhancer; and


- 10 B) reacting the product of step A) with a nucleophilic agent comprising a sulfur atom.

2. A method according to claim 1 in which the coupling agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).

- 15 3. A method according to claim 2, in which the coupling agent is the hydrochloride salt of EDC.


4. A method according to any of the preceding claims, in which the coupling enhancer is selected from the group consisting of:

- A) a heterocyclic ring containing one or two nitrogen atoms, said ring being optionally  
 20 substituted; such as a compound of formula (D) or formula (E),



- wherein  $R_{11}$  and  $R_{12}$  can be the same or different, and each represent a hydrogen atom or a  
 25 cyano group;  $R_{13}$  represent a hydrogen atom or an alkyl group; and  $R_{14}$  represent a hydrogen atom or a salt of a sulfonic acid such as sodium sulfonate  $[-S(=O)(=O)-O^- Na^+]$ ; and  
 B) an unsaturated 5-6 membered heterocyclic ring fused to an aromatic- or heteroaromatic ring  
 in which the said heterocyclic ring contains three nitrogen atoms, said rings being optionally  
 substituted, such as a compound of formula (F) or formula (G),

30



X = H, F, Cl, Br and Y = CH, N, O, S

AMENDED SHEET

6. Dec. 2004 18:52

Nr. 0454 S. 8

2003-100 PC

preferably 6-chloro-hydroxybenzotriazole (6-Cl-HOBT), 7-aza-hydroxybenzotriazole (HOAt), or 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine (Dbht-OH).

5. A method according to any of the preceding claims, where the nucleophilic agent comprising a sulfur atom is selected from the group comprising:

- compounds of formula  $[M]^+ [SH]^-$  wherein M is a metal such as Li, Na or K; or  $[M]^{2+} [S]^{2-}$  wherein M is a metal such as Ca or Mg, the said sulfide salts being optionally hydrated (such as sodium hydrosulfide hydrate); and


10 - an *in situ* generated sulfide salt or a hydrated sulfide salt.

6. The method of any of the preceding claims, wherein the nucleophilic agent is dissolved in a suitable solvent prior to addition to the reaction mixture, or wherein the nucleophilic agent is added in the form of a solid salt or as a solution of the salt in water and/or an organic solvent or

15 a combination thereof.

7. A method according to any of the preceding claims for preparing a steroidal carbothioic acid of formula (IV) or a salt thereof

20



Wherein the symbol  $\text{---}$  in the 1,2-position represent a single or a carbon-carbon double bond;


- 25  $R_1$  represents a hydrogen atom, a hydroxy- or an alkoxy group (such as an optionally substituted  $C_{1-6}$  alkoxy) in the  $\alpha$ -configuration, a group  $-O-C(=O)-R_6$ , where  $R_6$  is an alkyl group (such as optionally substituted  $C_{1-6}$  alkyl) or an optionally substituted 5-6 membered heterocyclic ring containing either oxygen, nitrogen or sulfur as ring hetero atom (such as a furanyl-, pyrrolyl- or a thiophenyl group);
- 30  $R_2$  represents a hydrogen atom, a hydroxy group, an alkoxy group (such as an optionally substituted  $C_{1-6}$  alkoxy) in the  $\alpha$ -configuration, an alkyl group (such as an optionally substituted  $C_{1-6}$  alkyl) which may be in either the  $\alpha$ - or  $\beta$ -configuration, an alkylene group (such as an optionally substituted  $C_{1-6}$  alkylene having the two free valences on the same carbon atom,

6. Dec. 2004 18:52


Nr. 0454 S. 9

2003-100 PC

preferably methylene) [the alkylene group bound to the steroid nucleus via a double bond] or  $R_1$  and  $R_2$  together represent



- 5 where  $R_7$  and  $R_8$  are the same or different and each represent a hydrogen atom or an alkyl group (such as an optionally substituted  $C_{1-6}$  alkyl);  
 $R_3$  represent a hydrogen atom, hydroxy- or a protected hydroxy group in either the  $\alpha$ - or  $\beta$ -configuration or an oxo group (in which case the bond between  $R_3$  and the steroid nucleus is a double bond);
- 10  $R_4$  represents a hydrogen- or a halogen atom or  $R_3$  and  $R_4$  together represent a carbon-carbon bond or an epoxy group in the  $\beta$ -configuration; and  
 $R_5$  represents a hydrogen- or a halogen atom in either the  $\alpha$ - or  $\beta$ -configuration;  
 $R_9$  represents a hydrogen atom or  $R_9$  represent a metal ion (eg. the moiety  $-S-R_9$  represents a group of the formula  $[-S]^- [M]^+$  wherein M is a metal such as Li, Na or K); the method
- 15 comprising;
- A) reacting a steroidal carboxylic acid of formula (II) or a salt thereof



- 20 in which the substituents of formula (II) have the above defined meaning with a coupling agent alone or in conjunction with an coupling enhancer, followed by the reaction with a nucleophilic agent comprising a sulfur atom; and optionally
- B) reacting the product from step A) with an acid.
- 25 8. The method of any of the preceding claims, wherein 1)
- the coupling agent is added before the coupling enhancer, or
  - the coupling enhancer is added before the coupling agent, and/or wherein 1)
  - the steroidal carboxylic acid is added to a mixture of the coupling agent and the coupling enhancer, or wherein
- 30 - a mixture of the coupling agent and the coupling enhancer is added to a steroidal carboxylic acid, or wherein

6. Dec. 2004 18:52


Nr. 0454 S. 10

2003-100 PC

- the steroidal carboxylic acid is added to a mixture of the coupling agent and the coupling enhancer in a polar aprotic solvent, preferably DMF or DMA, at elevated temperature.

- 5 9. A method for preparing a steroidal carbothioate (i.e. the ester of the steroidal carbothioic acid), or a salt thereof, the method comprising:  
reacting a steroidal carbothioic acid or a salt thereof, which is prepared as defined in any of the preceding claims, with an electrophilic agent.
- 10 10. A method according to claim 9, in which the electrophilic agent is selected from the group consisting of:  $C_{1-8}$  di- or trihaloalkanes, preferably a trihalo- or a dihalomethane, such as chlorobromomethane or bromofluoromethane.
11. A method according to claim 9 or 10 for preparing a steroidal carbothioate of formula (I)


15



wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_5$  are defined as in claim 7; and

$R_{10}$  represents a  $C_{1-8}$  haloalkyl or an optionally substituted heterocyclic ring, the method comprising:

- 20 A) reacting a steroidal carboxylic acid of formula (II)




with a coupling agent and a coupling enhancer [such as a compound of formula (D) or formula (E)]

25

6. Dec. 2004 18:52

Nr. 0454 S. 11

2003-100 PC



wherein  $R_{11}$  and  $R_{12}$  independently represent a hydrogen atom or a cyano group ( $C\equiv N$ );


$R_{13}$  represent a hydrogen atom or an alkyl group; and

5  $R_{14}$  represent a hydrogen atom or a moiety of a sulfonic acid, such as sodium sulfonate (eg. the group  $-S(=O)(=O)-O Na^+$ );

B) reacting the product from step A) with a nucleophilic agent comprising sulfur; and

C) reacting the product from step B) with an electrophilic agent [such as a  $C_{1-6}$  di- or trihaloalkane, preferably a trihalo- or a dihalomethane such as chlorofluoromethane or

10 bromofluoromethane] or a compound of the following formula;



wherein  $X=H, F, Cl, Br$  and;  $Y=CH_2, NH, O, S$ , preferably  $X=Cl$  and  $Y=O$ .

15

12. The method of claim 11, wherein the coupling enhancer is selected from the group consisting of: NMI (N-methylimidazole); DCI (4,5-dicyanimidazole); NHS (N-hydroxysuccinimide); and sulfo-NHS (N-hydroxysulfosuccinimide).

20 13. The method of any of the claims 11-12, wherein step C) constitutes the *in situ* reaction of the product from step B) with bromofluoromethane to form a compound of formula (I) wherein  $R_{10}$  is a fluoromethyl group, such as fluticasone propionate.

14. The method according to any of the preceding claims, in which

- 25 - at least two subsequent steps are performed *in situ*, i.e. without any change or removal of solvents, or isolation of the individual intermediates; and/or
- the method is conducted as a continuous method; and/or
  - step A), B) and optionally step C) are conducted as a one-pot synthesis without solvent changes and/or are performed at room or elevated temperature.

30

15. The method of any of the claims 9-14, wherein an androstane 17 $\beta$ -carboxylic acid is converted to an androstane 17 $\beta$ -carbothioate.


16. The method of any of the preceding claims, wherein step B) provides an alkali metal salt of  
35 the thioic acid, such as a compound of formula (IV), in which the moiety  $-S-R_5$  represent a

6. Dec. 2004 18:52

Nr. 0454 S. 12


2003-100 PC

group of the formula  $[-S]^-[M]^+$  wherein M is a metal such as Li, Na or K e.g.  $-S^-Na^+$ , and the other substituents have the same meaning as defined in claim 7.





5

17. A compound of the formula (III) and salts and solvates thereof



10 wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ , and  $R_5$  are defined as in claim 7; and

Z represent the structural moiety resulting from the reaction between the steroidal carboxylic acid of formula (II) and a coupling agent (preferably EDC), followed by a coupling enhancer selected from the group consisting of the compounds of formulas (D); (E); (F); and (G):



15

wherein  $R_{11}$  and  $R_{12}$  independently represent a hydrogen atom or a cyano group;  $R_{13}$  represent a hydrogen atom or a methyl group; and  $R_{14}$  represent a hydrogen atom or a moiety of a sulfonic acid, such as sodium sulfonate [ie. the group  $-S(=O)(=O)-O^-Na^+$ ],


20

6

6. Dec. 2004 18:52

Nr. 0454 S. 13

2003-100 PC



X - H, F, Cl, Br and Y - CH, N, O, S

with the proviso that:

- 5 when the coupling enhancer is a compound of formula (F), X can not represent H when Y represents CH;  
 When the coupling enhancer is a compound of formula (D), R<sub>11</sub> and R<sub>12</sub> can not both represent H when R<sub>1</sub> in formula III represents OH; and  
 when the coupling enhancer is a compound of formula (E), R<sub>14</sub> can not represent H when R<sub>1</sub> in  
 10 formula III represents H;

and with the further proviso that

- succinimidyl-9 $\alpha$ -fluoro-11 $\beta$ ,17 $\alpha$ -dihydroxy-16 $\alpha$ -methyl-3-oxoandrosta-1,4-diene-17 $\beta$ -carboxylate;  
 15 17 $\alpha$ -hydroxy-4-androsten-3-one-17 $\beta$ -carboxylic acid N-hydroxysuccinimide ester;  
 N-hydroxysuccinimidyl-9-fluoro-16 $\alpha$ -methyl-11 $\beta$ ,17-dihydroxy-3-oxo-1,4-androstadiene-17 $\beta$ -carboxyester;  
 N-hydroxysuccinimide ester of dexamethasone-17 $\beta$ -carboxylic acid; and  
 1-[(9 $\alpha$ -fluoro-11 $\beta$ -hydroxy-16 $\beta$ -methyl-3-oxo-17 $\alpha$ -propionyloxyandrosta-1,4-dien-17 $\beta$ -  
 20 yl)carbonyl]imidazole are disclaimed.


18. The compound of claim 17, wherein at least one of R<sub>11</sub> and R<sub>12</sub> is a cyano group (C $\equiv$ N), and/or R<sub>13</sub> is a hydrogen atom, and/or formula (D) is NMI (N-methylimidazole) or DCI (4,5-dicyano-imidazole), and/or formula (E) is NHS (N-hydroxysuccinimide) or sulfo-NHS (N-  
 25 hydroxysulfosuccinimide).

19. The compound having the formula:

6. Dec. 2004 18:53

Nr. 0454 S. 14


2003-100 PC



In which the substituents have the same meaning as defined in claim 17, and salts and solvates thereof, with the proviso that R14 can not represent H when R1 represents H.

5

20. A compound of the formula (VI) and salts and solvates thereof



10 wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are defined as in claim 7; and

R<sub>a</sub> and R<sub>b</sub> are defined as in claim 1;

with the proviso that 1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide-6 $\alpha$ ,9 $\alpha$ -difluoro-11 $\beta$ -hydroxy-16 $\alpha$ ,17 $\alpha$ -isopropylidenedioxy-3-oxo-androsta-1,4-diene-17 $\beta$ -carboxylate is disclaimed.

15 21. A composition comprising a compound as defined in any of claims 17-20.

22. Use of a compound of any of the claims 17-20 as an intermediate in a method for preparing a steroidal carbothioate or a steroidal carbothioic acid, such as in a method for preparing fluticasone propionate.

20

23. Use according to claim 22, in which the method comprises reaction with a nucleophilic agent comprising a sulfur atom and/or comprises reaction with an electrophilic agent.

x